RxDoctor Payments Data

Summer Afaneh, APRN

Family · Cleveland, OHNPI 1043782923

Payments from drug & device makers

$542in general payments, 2019–2025

Across 26 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$101
  • Otsuka America Pharmaceutical, Inc.$59
  • E.r. Squibb & Sons, L.L.C.$54
  • Exact Sciences$49
  • Lilly USA, LLC$48
  • Mannkind Corporation$43
  • plus $189 from 9 others

What the payments were for

  • Food & beverage$49992%
  • Education$438%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$542 in reported general payments places this provider in the 60th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$153,561
Medicare patients
390
Services billed
1,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$92,252
JardianceEmpagliflozin102$43,481
Invega SustennaPaliperidone Palmitate15$36,616
JanuviaSitagliptin Phosphate70$23,832
XareltoRivaroxaban23$17,958
Pantoprazole Sodium341$10,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,086
Potassium Chloride235$8,655
Tresiba Flextouch U-100Insulin Degludec16$8,447
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$8,049
Atorvastatin Calcium474$6,510
Incruse ElliptaUmeclidinium Bromide16$6,127
Fluphenazine Hcl21$5,647
Divalproex Sodium124$5,493
Gabapentin203$4,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$92,252302 claims
Boehringer IngelheimJardiance$13$43,481102 claims
GSKTrelegy Ellipta, Incruse Ellipta$21$16,21431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,812 family providers in Ohio.

Other family in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →